Kappos L, Heun R, Mertens H G
Max-Planck-Society, Clinical Research Unit for Multiple Sclerosis, Würzburg, Federal Republic of Germany.
Eur Arch Psychiatry Clin Neurosci. 1990;240(1):34-8. doi: 10.1007/BF02190090.
In a retrospective matched-pairs study the efficacy of azathioprine treatment was compared with no treatment over a period of at least 10 years. Of 277 patients with clinically definite multiple sclerosis seen during the years 1973 and 1974, 42 pairs were selected by similarity in disability score, sex, age and disease duration. Only 3 patients were lost to follow-up, and in 2 cases the initial diagnosis could not be confirmed. At the end of the 10-year period the number of wheelchair-bound, bedridden or deceased patients was double in the untreated as compared with the azathioprine-treated group but the number of non- or only minimally handicapped patients was similar in each group. The mean disability score was significantly lower in the treated group. Although caution is warranted as in every retrospective study because of insufficiently controlled confounding variables, these results support a positive but weak long-term effect of azathioprine.
在一项回顾性配对研究中，对硫唑嘌呤治疗至少10年的疗效与未治疗进行了比较。在1973年至1974年期间确诊的277例临床确诊的多发性硬化症患者中，根据残疾评分、性别、年龄和病程的相似性选取了42对。仅3例患者失访，2例患者的初始诊断无法得到证实。在10年期末，与硫唑嘌呤治疗组相比，未治疗组中需要轮椅辅助、卧床或死亡的患者数量增加了一倍，但两组中无残疾或仅有轻微残疾的患者数量相似。治疗组的平均残疾评分显著更低。尽管由于混杂变量控制不足，每项回顾性研究都需要谨慎对待，但这些结果支持硫唑嘌呤具有积极但微弱的长期疗效。
